Quick Answer
Jazz Pharmaceuticals plc reported Cash And Cash Equivalents At Carrying Value of $1.39 billion for the year ending 2025.
- Jazz Pharmaceuticals plc showed a decrease of -42.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Jazz Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), Jazz Pharmaceuticals plc's Cash And Cash Equivalents At Carrying Value has grown by 5,489.3%.
- Historical annual values: Fiscal year 2025: $1.39 billion | Fiscal year 2024: $2.41 billion | Fiscal year 2023: $1.51 billion | Fiscal year 2022: $881.48 million | Fiscal year 2021: $591.45 million | Fiscal year 2020: $1.06 billion | Fiscal year 2019: $637.34 million | Fiscal year 2018: $309.62 million | Fiscal year 2017: $386.04 million | Fiscal year 2016: $365.96 million | Fiscal year 2015: $988.79 million | Fiscal year 2014: $684.04 million | Fiscal year 2013: $636.50 million | Fiscal year 2012: $387.20 million | Fiscal year 2011: $82.08 million | Fiscal year 2010: $44.79 million | Fiscal year 2009: $15.60 million | Fiscal year 2008: $24.90 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: